Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

P Gantner; L Cuzin; C Allavena; A Cabie; P Pugliese; M-A Valantin; F Bani-Sadr; V Joly; T Ferry; I Poizot-Martin; R Garraffo; G Peytavin; S Fafi-Kremer; D Rey; Dat'AIDS study group

doi:10.1111/hiv.12506

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

HIV Med. 2017 Oct;18(9):704-708. doi: 10.1111/hiv.12506. Epub 2017 Apr 26.

Authors

P Gantner¹, L Cuzin^{2

3

4}, C Allavena⁵, A Cabie⁶, P Pugliese⁷, M-A Valantin^{8

9}, F Bani-Sadr¹⁰, V Joly¹¹, T Ferry¹², I Poizot-Martin¹³, R Garraffo¹⁴, G Peytavin^{15

16}, S Fafi-Kremer¹, D Rey¹⁷; Dat'AIDS study group

Collaborators

Dat'AIDS study group:
E Billaud, C Biron, B Bonnet, S Bouchez, D Boutoille, C Brunet, T Jovelin, N Hall, C Bernaud, P Morineau, V Reliquet, O Aubry, P Point, M Besnier, O Grossi, M Lefebvre, H Hüe, M Cavellec, A Soria, S Pineau, E André-Garnier, A Rodallec, S Brégigeon, O Faucher, V Obry-Roguet, M Orticoni, M J Soavi, I Luquet-Besson, E Ressiot, I Pinot, M J Ducassou, H Bertone, S Gallie, S Trijau, A S Ritleng, A Ivanova, M Guignard, C Blanco-Betancourt, M Alvarez, N Biezunski, A Debard, P Delobel, C Delpierre, C Fourcade, B Marchou, G Martin-Blondel, L Porte, M Mularczyk, D Garipuy, K Saune, I Lepain, M Marcel, E Puntis, C Ceppi, E Cua, J Cottalorda, P Dellamonica, E Demonchy, B Dunais, J Durant, C Etienne, S Ferrando, J G Fuzibet, K Risso, V Mondain, A Naqvi, N Oran, I Perbost, S Pillet, B Prouvost-Keller, C Pradier, S Wehrlen-Pugliese, E Rosenthal, S Sausse, P M Roger, Ph Choisy, S Vandame, Th Huleux, F Ajana, I Alcaraz, V Baclet, T H Huleux, H Melliez, N Viget, M Valette, E Aissi, Ch Allienne, A Meybeck, B Riff, R Agher, C Katlama, C Duvivier, Y Yazdanpanah, R Landman, C Mackoumbou-Nkouka, F Louni, Z Julia, C Charpentier, D Descamps, L Cotte, D Peyramond, C Chidiac, F Ader, F Biron, A Boibieux, P Miailhes, T Perpoint, I Schlienger, F Dahoud, J Lippmann, E Braun, J Koffi, C Longuet, V Guéripel, C Augustin-Normand, S Degroodt, M L Batard, C Bernard-Henry, C Cheneau, E de Mautort, P Fischer, M Partisani, M Priester, F Bani-Sadr, C Rouger, J L Berger, Y N'Guyen, D Lambert, I Kmiec, M Hentzien, D Lebrun

Affiliations

¹ Virology Laboratory, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
² INSERM, UMR 1027, Toulouse, France.
³ Université de Toulouse III, Toulouse, France.
⁴ CHU Toulouse, COREVIH Toulouse, Toulouse, France.
⁵ Infectious Diseases Department, CHU de Nantes, Nantes, France.
⁶ Infectious Diseases Department, CHU de Fort-de-France, Martinique, France.
⁷ Infectious Diseases Department, CHU de Nice, Nice, France.
⁸ Infectious Diseases Department, APHP Hôpital Pitié Salpêtrière, Paris, France.
⁹ Institut Pierre Louis d'épidémiologie et de Santé Publique (UMRS 1136), UPMC Univ Paris 06, INSERM, Sorbonne Universités, Paris, France.
¹⁰ Infectious Diseases Department, CHU de Reims, Reims, France.
¹¹ Infectious Diseases Department, APHP Hôpital Bichat, Paris, France.
¹² Infectious Diseases Department, Hospices civils de Lyon, Lyon, France.
¹³ APHM Hôpital Sainte-Marguerite, Immuno-Hematology Clinic, Aix-Marseille University, Marseille, France.
¹⁴ Pharmacology Laboratory, CHU de Nice, Nice, France.
¹⁵ AP-HP, Pharmacology Laboratory, Hôpital Bichat-Claude Bernard, Paris, France.
¹⁶ IAME, UMR 1137, Sorbonne Paris Cité, INSERM, Université Paris Diderot, Paris, France.
¹⁷ Le Trait d'Union, HIV-Infection Care Center, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

PMID: 28444816
DOI: 10.1111/hiv.12506

No abstract available

Publication types

Letter

MeSH terms

Anti-HIV Agents / administration & dosage*
Anti-HIV Agents / pharmacology
Cohort Studies
Drug Therapy, Combination
Female
HIV Infections / drug therapy*
HIV-1 / drug effects
Heterocyclic Compounds, 3-Ring / administration & dosage*
Heterocyclic Compounds, 3-Ring / pharmacology
Humans
Male
Middle Aged
Oxazines
Piperazines
Pyridones
Retrospective Studies
Rilpivirine / administration & dosage*
Rilpivirine / pharmacology
Treatment Outcome

Substances

Anti-HIV Agents
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
dolutegravir
Rilpivirine